(Exact name of small business issuer as specified in its charter)
(State or other jurisdiction of incorporation or organization)
(IRS Employer Identification No.)
(Address of principal executive offices)
(Registrant's Telephone number)
(Former Name or Former Address, if Changed Since Last Report)
On January 10, 2014, FluoroPharma Medical, Inc. (the "Company") conducted the final closing under the securities purchase agreement dated as of December 31, 2013 (the "Purchase Agreement"). In the aggregate, the Company issued 1,755,000 shares of common stock and warrants to purchase 1,755,000 shares of common stock for a total purchase price of $877,500 pursuant to the Purchase Agreement. Brookline Group, LLC and Monarch Capital acted as the Company's placement agents in connection with the private placement and received aggregate cash fees of $69,400 and five-year warrants to purchase an aggregate of 173,500 shares of common stock at an exercise price of $0.83 per share.
For a more complete description of the private placement, please refer to the Current Report on Form 8-K filed by the Company on January 7, 2014.
FluoroPharma Medical, Inc. |
By: | /s/ Johan M (Thijs) Spoor |
Name: Johan M (Thijs) Spoor | |
Title: CEO and President |